New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:01 EDTAMGNXencor initiates Phase 1b/2a trial of XmAb5871
Xencor announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb5871 in patients with moderate to severe rheumatoid arthritis.  XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone payment of an undisclosed amount to Xencor from Amgen. XmAb5871 is a humanized and Fc engineered monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by co-engaging CD19 and CD32b. Amgen and Xencor entered into an option and co-development agreement for XmAb5871 in January 2011. Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time and is eligible for early development milestone payments.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
17:25 EDTAMGNAmgen announces AMG 416 study met its primary and all secondary endpoints
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, SHPT, in patients with chronic kidney disease,CKD, receiving hemodialysis, met its primary and all secondary endpoints. "The results from this second Phase 3 study help to confirm that AMG 416 could become an important new treatment option for dialysis patients with secondary hyperparathyroidism," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite the variety of options available for the treatment of this disease, an unmet need remains for an intravenous therapy that can be administered along with hemodialysis. We look forward to sharing results of a head-to-head study evaluating AMG 416 compared to cinacalcet next year."
August 15, 2014
06:54 EDTAMGNAmgen shares should 'grind higher' this year, says RBC Capital
RBC Capital expects Amgen shares to "grind higher" this year driven by a greater appreciation of pipeline programs, the Analyst Day on October 28, an expected filing of the PCSK-9 program soon, and positive Ph iiB anti-CGRP migraine data expected year-end. Shares are Outperform rated.
August 14, 2014
12:01 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
11:52 EDTAMGNThird Point discloses new stakes in Finisar, Amgen, Ally Financial
August 13, 2014
18:55 EDTAMGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Aspen Technology (AZPN), up almost 3% after reporting better than expected Q4 results and giving Q1 and FY15 guidance on its earnings conference call. ALSO HIGHER: Kindred Healthcare (KND), up more than 1% after Point72 reported a 5.1% passive stake in the company. DOWN AFTER EARNINGS: Cisco Systems (CSCO), down 1.2% after reporting Q4 results, giving Q1 guidance, and announcing that it is cutting 8% of its workforce... Noodles & Company (NDLS), down 21.2% after reporting Q2 results and "tempering" its FY14 outlook... Conatus Pharmaceuticals (CNAT), down 13.6% after reporting Q2 results and announcing it is deferring the results of its NAFLD/NASH clinical trial to 1Q15. ALSO LOWER: Amgen (AMGN), down 2.15% after announcing the Phase 3 Kyprolis FOCUS clinical trial did not meet its primary endpoint.
16:17 EDTAMGNAmgen issues voluntary recall of Aranesp prefilled syringes in several countries
Subscribe for More Information
16:09 EDTAMGNAmgen slips lower after hours, levels to watch
Subscribe for More Information
16:04 EDTAMGNAmgen says Phase 3 clinical trial FOCUS did not meet primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use